54 Results for "

T-cell receptor signaling

" in MedChemExpress (MCE) Product Catalog:
Products (54)

54 Results for "T-cell receptor signaling" in MCE Product Catalog:

6
6 Publications Verification
Cat. No.: HY-126675A
CAS No.: 2241300-51-4
Purity:  99.94%
Research Areas:  

Inflammation/Immunology

AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
loading...
    loading...
6
6 Publications Verification
Cat. No.: HY-126675
CAS No.: 2241300-50-3
Purity:  99.68%
Research Areas:  

Inflammation/Immunology

AS2863619 free base is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 free base targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 free base also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 free base exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 free base can be applied to research in related fields such as periodontitis-induced bone defects .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-130254
CAS No.: 2380027-49-4
Purity:  98.04%
Target:  

Src

Research Areas:  

Inflammation/Immunology Cancer

CSK-IN-1 (compound 13) is a potent, orally active c-terminal Src kinase (CSK) with IC50 values below 3 nM and 4 nM in CSK HTRF and Caliper assay, respectively. CSK-IN-1 shows the ability to increase T cell proliferation induced by T cell receptor signaling .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-135892
CAS No.: 2680616-96-8
Purity:  99.23%
Target:  

MAP4K

Research Areas:  

Inflammation/Immunology

GNE-1858 is a potent and ATP-competitive hematopoietic progenitor kinase-1 (HPK1) inhibitor, with IC50s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA, respectively .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P10102
CAS No.: 629628-53-1
Research Areas:  

Inflammation/Immunology Cancer

Kp7-6 is a Fas mimetic peptide and also a Fas/FasL antagonist. Kp7-6 specifically binds to Fas and FasL, disrupts receptor complexes, and blocks downstream apoptosis signaling pathways. Kp7-6 inhibits the phosphorylation of ERK1-2, induces the phosphorylation of IκBα, and activates NF-κB. Kp7-6 inhibits the activation of caspase-8, caspase-3 and JNK, and suppresses human amylin-induced β-cell apoptosis. Kp7-6 inhibits FasL-induced lymphoid cytotoxicity and apoptosis. Kp7-6 reduces local tumor FasL expression, increases CD8 +Fas + T cell infiltration, and decreases tumor volume in pancreatic neuroendocrine tumor models. Kp7-6 prevents concanavalin A-induced liver injury in mice. Kp7-6 is applicable to research related to type 2 diabetes, concanavalin A-induced hepatitis and pancreatic neuroendocrine tumors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-109038
CAS No.: 509092-16-4
Synonyms: KRP-203 free base
Mocravimod (KRP-203 free base) is a sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod retains T cell effector function. Mocravimod can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13660
CAS No.: 509088-69-1
Purity:  99.68%
Synonyms: KRP-203
Mocravimod (hydrochloride) is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod (hydrochloride) preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod (hydrochloride) significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod (hydrochloride) retains T cell effector function. Mocravimod (hydrochloride) can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0910
CAS No.: 155683-00-4
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 + T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca 2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P76687
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: UBASH3A; Ubiquitin Associated And SH3 Domain Containing A; STS-2; CLIP4; TULA; Ubiquitin-Associated And SH3 Domain-Containing Protein A; Suppressor Of T-cell receptor signaling 2; T-cell Ubiquitin Ligand Protein; T-cell Ubiquitin Ligand 1; Cbl-Interacting
Species:  
Human
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-P99315
CAS No.: 220651-94-5
Synonyms: BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-156659
CAS No.: 445406-82-6
Target:  

Phosphatase ERK

Research Areas:  

Inflammation/Immunology

NC1 is a selective non-competitive and allosteric lymphoid-specific tyrosine phosphatase (LYP) inhibitor, with a Ki value 4.3 μM. NC1 allosterically regulates LYP/PTPN22 activity by restricting WPD loop movement. NC1 inhibits LYP activity in lymphoid T cells and enhances T-cell receptor signaling. NC1 can be used for the research of autoimmune diseases .
loading...
    loading...
Cat. No.: HY-P5005
CAS No.: 125093-93-8
Target:  

CMV PD-1/PD-L1

VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis .
loading...
    loading...
Cat. No.: HY-148691
CAS No.: 2655638-07-4
Purity:  95.01%
Target:  

PROTACs Phosphatase

Research Areas:  

Metabolic Disease Cancer

PROTAC PTPN2 degrader-1 is a PROTAC degrader targeting non-receptor protein tyrosine phosphatase 2 (PTPN2), with a DC50 of 18 nM in 293T cells. It exhibits an IC50 of 22 nM against PTPN2. Through highly selective degradation and inhibition of PTPN2 phosphatase, PROTAC PTPN2 degrader-1 relieves the negative regulation of the IFNγ pathway, upregulates interferon signaling, activates effector T cells, and enhances anti-tumor immunity. PROTAC PTPN2 degrader-1 can be used in melanoma-related research .
loading...
    loading...
Cat. No.: HY-P991336
CAS No.: 2708115-83-5
Synonyms: INBRX-106; ES-102
Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4 + and CD8 + T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer .
loading...
    loading...
Cat. No.: HY-P991201

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).
loading...
    loading...
Cat. No.: HY-116330
CAS No.: 11079-53-1
Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca 2+ levels by activating Ca 2+-conducting non-selective canonical TRPC6 channels and triggers adipose tissue thermogenesis via the Dlat-AMPK signaling axis to suppress obesity. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .
loading...
    loading...
Cat. No.: HY-P99292
CAS No.: 326859-36-3
Synonyms: HuZAF; Anti-Human IFNG Recombinant Antibody

Target:  

IFNAR

Research Areas:  

Inflammation/Immunology

Fontolizumab (HuZAF) is a human monoclonal antibody targeting interferon γ (IFN-γ). Fontolizumab binds specifically and with high affinity to secreted IFN-γ, neutralizes its activity, blocks receptor binding, and inhibits downstream signal transduction and the expression of IFNγ-responsive genes. Fontolizumab reduces serum C-reactive protein levels, inhibits the expression of IL-1α, IL-1β and IL-12Rβ2, and decreases the number of IFNγ-producing T cells in activated peripheral blood mononuclear cells. Fontolizumab can be used in research related to Crohn's disease .
loading...
    loading...
Cat. No.: HY-P99266
CAS No.: 652153-01-0
Synonyms: Anti-Human CD4 Recombinant Antibody
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
loading...
    loading...
Cat. No.: HY-P11288
CAS No.: 2871680-36-1
Research Areas:  

Cancer

ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .
loading...
    loading...
Cat. No.: HY-P11288A
Research Areas:  

Cancer

ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .
loading...
    loading...